Company overview
Basic information
Company name
DG Paupys, UAB
Company code
303437385
VAT code
LT100010272018
Registered address
Vilnius, Aukštaičių g. 7, LT-11341
Registration date
2014-10-27
Company age: 12 y.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://darnugroup.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Development of building projects
Ownership form
Private without foreign capital
UAB "DG Paupys"
Company code: 303437385
Address: Vilnius, Aukštaičių g. 7, LT-11341
VAT code: LT100010272018
Description
This description was generated by artificial intelligence.
DG Paupys, UAB (company code 303437385) is an operational private limited liability company registered in 2014. It is a private company under Lithuanian ownership, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital, and it is governed by a CEO only. The company is based in Vilnius, Aukštaiciu g. 7, Vilniaus m. sav., Vilniaus apskr. Its main activity is classified under EVRK M.68.12.00, Development of building projects. The share capital is EUR 3.00 million. Financially, 2025 was the latest reported year. Revenue amounted to EUR 8.59 million, compared with EUR 12.14 million in 2024 and EUR 477.0 thousand in 2023. Net profit in 2025 was EUR 1.22 million, down from EUR 2.31 million in 2024 but above the 2023 loss of EUR 392.8 thousand. Profit margin was 14.1% in 2025, after 19.0% in 2024 and -82.4% in 2023. At the end of 2025, equity stood at EUR 5.09 million, liabilities at EUR 3.09 million, and total assets at EUR 8.18 million.
Download a detailed company report
Make confident decisions with all the information about DG Paupys, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.